Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
JCO Precision Oncology · 2024-04 · (8)
DOI: 10.1200/po.23.00274 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-04. Verfasst von Andrew T Lenis und 33 weiteren Autor:innen. Beteiligte Einrichtung: Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center (MSK), New York, NY. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to evaluate the natural history and genomic landscape of chemotherapy-resistant bladder cancer to inform patient management and clinical trials. METHODS Data were collected on patients with clinically localized muscle-invasive urothelial bladder cancer treated with NAC and cystectomy at our institution between May 15, 2001, and August 15, 2019, and completed four cycles of gemcitabine and cisplatin NAC, excluding those treated with adjuvant therapies. Survival was estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards models were used to identify predictors of recurrence-free survival (RFS). Genomic alterations were identified in targeted exome sequencing (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets) data from post-NAC specimens from a subset of patients. RESULTS Lymphovascular invasion (LVI) was the strongest predictor of RFS (hazard ratio, 2.15 [95% CI, 1.37 to 3.39]) on multivariable analysis. Patients with ypT2N0 disease without LVI had a significantly prolonged RFS compared with those with LVI (70% RFS at 5 years). Lymph node yield did not affect RFS. Among patients with sequencing data (n = 101), chemotherapy-resistant tumors had fewer alterations in DNA damage response genes compared with tumors from a publicly available chemotherapy-naïve cohort (15% v 29%; P = .021). Alterations in CDKN2A/B were associated with shorter RFS. PIK3CA alterations were associated with LVI. Potentially actionable alterations were identified in more than 75% of tumors. CONCLUSION Although chemotherapy-resistant bladder cancer generally portends a poor prognosis, patients with organ-confined disease without LVI may be candidates for close observation without adjuvant therapy. The genomic landscape of chemotherapy-resistant tumors is similar to chemotherapy-naïve tumors. Therapeutic opportunities exist for targeted therapies as adjuvant treatment in chemotherapy-resistant disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center (MSK), New York, NY.
- Department of Urology, Columbia University Irving Medical Center, New York, NY.
- Biostatistics Service, Department of Epidemiology & Biostatistics, MSK, New York, NY.
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology, MSK, New York, NY.
- Genitourinary Oncology Service, Department of Medicine, MSK, New York, NY.
- Computational Oncology Service, Department of Epidemiology & Biostatistics, MSK, New York, NY.
ORCID-Profile: Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran, Jacob E Tallman, Syed M Alam, Carissa E Chu, Manual De Jesus Escano, Emily Bochner, Peter A Reisz, Hong Truong, Victor McPherson, Min Yuen Teo, Samuel Funt, David Aggen, Timothy F Donahue, Eugene K Cha, Nikolaus Schultz, Michael F Berger, Dean F Bajorin, Jonathan E Rosenberg, Bernard H Bochner, Hikmat Al-Ahmadie, David B Solit, Gopa Iyer
Förderung
- NCI NIH HHS
Zitieren
APA
Lenis, A. T., Whiting, K., Ravichandran, V., Tallman, J. E., Alam, S. M., Chu, C. E., Jesus Escano, M., Bochner, E., Katims, A., Reisz, P. A., Truong, H., Clinton, T. N., Telis, L., Dason, S., McPherson, V., Teo, M. Y., Funt, S., Aggen, D., Goh, A. C., …, & Pietzak, E. J. (2024). Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00274
Vancouver
Lenis AT, Whiting K, Ravichandran V, Tallman JE, Alam SM, Chu CE, et al. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00274
BibTeX
@article{Lenis2024,
author = {Lenis, Andrew T and Whiting, Karissa and Ravichandran, Vignesh and Tallman, Jacob E and Alam, Syed M and Chu, Carissa E and Jesus Escano, Manual De and Bochner, Emily and Katims, Andrew and Reisz, Peter A and Truong, Hong and Clinton, Timothy N and Telis, Leon and Dason, Shawn and McPherson, Victor and Teo, Min Yuen and Funt, Samuel and Aggen, David and Goh, Alvin C and Donahue, Timothy F and Cha, Eugene K and Donat, S Machele and Herr, Harry W and Dalbagni, Guido and Schultz, Nikolaus and Berger, Michael F and Bajorin, Dean F and Rosenberg, Jonathan E and Bochner, Bernard H and Ostrovnaya, Irina and Al-Ahmadie, Hikmat and Solit, David B and Iyer, Gopa and Pietzak, Eugene J},
title = {Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.23.00274}
}
EUVIMED